Pharmacies see the exact patients most likely to have undiagnosed sleep apnea, every single day. Here's why that matters right now.
A pharmacist fills the same blood pressure prescription for the same patient, month after month, for years. The patient picks up, nods, leaves.
What almost never gets asked is why that number won't come down, no matter what's in the bag.
Why are so many undiagnosed sleep apnea patients walking into pharmacies every day?
Close to 30 million Americans have obstructive sleep apnea, and roughly 80% of them don't know it.¹ Research puts overall prevalence at 26% of adults between 30 and 70.²
Untreated OSA actively worsens the exact conditions pharmacies already manage daily: hypertension, type 2 diabetes, stroke risk, depression.¹ A pharmacy counter isn't adjacent to this problem. It's standing on top of it.
The average independent community pharmacy fills around 191 prescriptions a day.³ A large share are for the conditions OSA makes worse: blood pressure medication, diabetes management, often both for the same patient.
That's a daily, recurring point of contact with the population most likely to have undiagnosed sleep apnea. It's also happening at a counter that already has trust built in, not a specialist's office the patient has never met.
For most of modern sleep medicine, treatment meant one thing: a CPAP machine. That changed in December 2024, when the FDA approved Zepbound (tirzepatide) as the first prescription medication for moderate-to-severe OSA in adults with obesity.⁴
In the trials behind that approval, the drug reduced breathing disruptions by roughly 25 to 29 events per hour, compared to 5 to 6 on placebo. Up to half of participants no longer met the criteria for OSA after a year.⁵
The number that drives this decision is the AHI, the apnea-hypopnea index, which counts breathing interruptions per hour. An AHI of 5 to 14 is mild, 15 to 29 is moderate, 30 or higher is severe.⁶
A physician uses that number to route treatment, often toward medication or an appliance for patients who cannot tolerate CPAP when the case is mild to moderate, and toward PAP as the first-line option once someone crosses into severe territory. None of that routing decision happens at the pharmacy counter. What happens there is everything before it and everything after it.
None of this asks a pharmacy to become a sleep clinic or take on diagnosis. It asks for something smaller: noticing that the patient picking up their third blood pressure refill this year might be dealing with something nobody's ever asked about.
If a patient hasn't had a formal sleep apnea evaluation, the Soliish AI selfie experience for sleep wellness helps them learn about factors related to their sleep and think through what to raise with a qualified healthcare professional.
